Dynamic indices of fractalkine in ischemic stroke
Open Access
- 20 March 2025
- journal article
- Published by FSPSI SCFHHRP in Acta Biomedica Scientifica
- Vol. 10 (1) , 136-143
Abstract
Background. The problem of a personalized approach to patients with ischemic stroke does not lose its relevance. Research is being conducted aimed at searching for points of application in the pathogenesis of cerebral infarction and the possibility of influencing them in order to have a positive impact on the recovery prognosis of patients.The aim of the work. To study the level of fractalkine (FKN) in the blood serum of patients with ischemic stroke (atherothrombotic subtype) in dynamics. The data obtained in the future can serve as the basis for the possible use of fractalkine as one of the treatment options for patients with acute cerebral ischemia.Materials and methods. Sixty people took part in the study. Group I (control) – healthy people; Group II – patients with hypertensive crisis without signs of acute changes in target organs; Group III – patients with atherothrombotic pathogenetic subtype of ischemic stroke on the background of hypertensive crisis.Results. It was revealed that the level of fractalkine in patients with hypertensive crisis, and in patients on the first day after the development of ischemic stroke, was 3.2 times higher than in the control group (p < 0.001). The fractalkine content in the blood serum of patients with ischemic stroke remained high for ten days. The highest level was recorded on days 4–5 from the onset of the disease and exceeded the initial level by 27.5 % (p < 0.001). Positive correlations were established between fractalkine indicators and indicators of the NIHSS (National Institutes of Health Stroke Scale) and Rankin scales, and blood pressure (p < 0.001).Conclusion. Studying the role of fractalkine in the pathogenesis of cerebral infarction remains a promising direction. The results obtained with further research in this area may become the basis for the subsequent development of fundamentally new approaches in the treatment of patients with acute cerebral events.Keywords
This publication has 18 references indexed in Scilit:
- An overview of the role of chemokine CX3CL1 (Fractalkine) and CX3C chemokine receptor 1 in systemic sclerosisImmunity, Inflammation and Disease, 2024
- Microglia-induced neuroinflammation in hippocampal neurogenesis following traumatic brain injuryHeliyon, 2024
- Microglia regulate motor neuron plasticity via reciprocal fractalkine/adenosine signalingbioRxiv, 2024
- Microglial depletion after brain injury prolongs inflammation and impairs brain repair, adult neurogenesis and pro‐regenerative signalingGlia, 2023
- Concentration and proteolysis of CX3CL1 may regulate the microglial response to CX3CL1Glia, 2022
- Immune Pathways in Etiology, Acute Phase, and Chronic Sequelae of Ischemic StrokeCirculation Research, 2022
- Ischemic stroke and infection: A brief update on mechanisms and potential therapiesBiochemical Pharmacology, 2021
- The intracellular domain of CX3CL1 regulates adult neurogenesis and Alzheimer’s amyloid pathologyJournal of Experimental Medicine, 2019
- 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke AssociationJournal of Vascular Surgery, 2018
- Absolute and Relative Contraindications to IV rt-PA for Acute Ischemic StrokeThe Neurohospitalist, 2015